FDA approves all ages gene therapy for spinal condition / Beckers

Ella Jeffries / beckershospitalreview - The FDA approved Novartis’ Itvisma (onasemnogene abeparvovec-brve), the company’s first and only gene replacement therapy for spinal muscular atrophy in children 2 and older, as well as for teens and adults. The therapy is designed to address the genetic …

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

---

Monday, December 1, 2025, 4:21 am / permalink 16428 / 2 stories in 3 months

Related Stories

---

• FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 6 wks
• FDA rejects Corcept’s cortisol modulator triggering setback / 2 months
• FDA approves Rucaparib for advanced prostate cancer / 2 months
• FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 3 months
• FDA Approves Ziftomenib for AML Treatment / 3 months
• FDA updates Sarepta gene therapy label with severe warnings / 4 months
• Experimental therapy reduces seizures in children with Dravet syndrome / 11 days

Related Tags

---

StackHealth Time Machine

---